Skip to content

Ocular Therapeutix

US · OCUL #2978 by market cap Listed 1970
5.57 -0.29 -4.95%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 3.10 Cheap vs history 11th percentile
5-year average 16.09 · #311 of 515 in Biotechnology
P/E ratio -4.31 Expensive vs history 73rd percentile
5-year average -5.92 · forward -3.70
P/S ratio 27.12 Expensive vs history 71st percentile
5-year average 19.79 · forward 20.05 · #231 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Ocular Therapeutix (OCUL) 1.23B -3.87 2.78 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value10.72 Economic moatNone UncertaintyVery High

Trading 92.4% below Morningstar's fair value estimate.

Fair value

Ocular Therapeutix Inc is assigned a 4-star quantitative star rating, illustrating our stance that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 42% discount to our quantitative fair value estimate of $10.72 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The firm's valuation metrics increase our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its price to cash ratio of 2.4, which ranks in the bottom 30% globally. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. We believe this is a sign that shares could be undervalued.

Conversely, the firm's unfavorable dividend structure is potentially concerning. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. The firm's forward dividend yield of 0%, for example, lies in the bottom 30% globally. This could imply a planned dividend cut or relatively high share price, which, despite our favorable price/fair value ratio, is a negative attribute.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Ocular Therapeutix discussion 0 comments

Add a comment